You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康緣藥業(600557.SH)上半年淨利潤升20.44%至2.42億元
格隆匯 08-19 16:20

格隆匯8月19日丨康緣藥業(600557.SH)發佈2019年半年度報告,實現營業收入22.63億元,同比增長22.60%;歸屬於上市公司股東的淨利潤2.42億元,同比增長20.44%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2.37億元,同比增長23.83%;基本每股收益0.41元。

報告期內公司營業收入和淨利潤取得穩步增長,主要為以下幾個方面:

1、堅決落實年度計劃,持續提高公司營銷能力,繼續加快推進基層市場戰略,基層市場已經成為公司重要收入來源;

2、公司高度重視研發創新及已上市品種再研發,加大研發投入,並依託企業中藥製藥過程新技術國家重點實驗室、中成藥智能製造國家地方聯合工程研究中心、重大新藥創制企業大平台、國家認定企業技術中心、國家博士後科研工作站等國內領先的創新平台和技術優勢,為公司產品學術推廣提供有力支持,助力公司創新產品銷量穩步提升;

3、報告期內,公司持續推進全面質量管理和技術管理,進行工藝、質量提升研究,保證產品質量,提高產品競爭力,並通過集中生產、技術改進等措施節能降耗,提升運營效率與效益,不斷加強智能化升級改造和體系建設,保持中藥智能化製造領軍地位;

4、品種方面,公司銀杏二萜內酯葡胺注射液、金振口服液及其他2017年度新進醫保品種銷量均取得較快增長,改善了公司品種銷售結構,保障了公司的持續發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account